Support Us : info@JSRSD-society.org
MPS II is also known as Hunter syndrome , it named after the Canadian doctor Charles Hunter who first described two brothers with the disease in 1917.
MPS II is one of the mucopolysaccharide diseases and it has a wide range of symptoms that vary in severity, There is no cure for MPS diseases, but there are ways of managing and treating the problems they cause, including enzyme replacement therapies (ERT).
MPS II occurs in children may be carriers of the gene for MPS II, If the mother is a carrier, there is a 50% risk that any boy born will have the disease.
All families of children with MPS II should seek further information from their doctor or genetic counselor before planning to have more children.
There are tests available for carriers, so it is important for all female relatives on the mother’s side to seek advice from their doctor.
The disease occur when Children with MPS II are missing an enzyme called iduronate sulfates, which is essential in cutting up the mucopolysaccharides called dermatan and heparan sulphate. The incomplete broken down mucopolysaccharides remain stored in cells in the body causing progressive damage. Babies may show little sign of the disease, but as more and more cells become damaged, symptoms start to appear.
There is no cure for the diseas but There is a treatments such as enzyme replacement therapies that can help make the disease more manageable. On July 24, 2006, the FDA granted marketing approval for enzyme replacement therapy for the treatment for MPS II.
This is a rare condition affecting 1 in 100,000 to 1 in 150,000 males. There is an estimate in the United States that 1 in 25,000 births will result in some form of MPS.